• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States
Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.02.049. Online ahead of print.ABSTRACTThe annual direct medical cost attributable to human papillomavirus (HPV) in the United States over the period 2004-2007 was estimated at $9.36 billion in 2012 (updated to 2020 dollars). The purpose of this report was to update that estimate to account for the impact of HPV vaccination on HPV-attributable disease, reductions in the frequency of cervical cancer screening, and new data on the cost per case of treating HPV-attributable cancers. Based primarily on data from the literature, we estimated the annual direc...
Source: Vaccine - March 12, 2023 Category: Allergy & Immunology Authors: Patrick A Clay Trevor D Thompson Lauri E Markowitz Donatus U Ekwueme Mona Saraiya Harrell W Chesson Source Type: research

Human papillomavirus (HPV) in pregnancy - An update
Eur J Obstet Gynecol Reprod Biol. 2021 Jul 31;264:340-348. doi: 10.1016/j.ejogrb.2021.07.053. Online ahead of print.ABSTRACTHuman papilloma viruses (HPV) are small epitheliotropic DNA viruses, of which there are 200 genotypes, 40 of which are known to cause genital infections and are also oncogenic. HPV is the most common sexually transmitted infection. Clinical features vary from asymptomatic (identified at routine cervical cancer screening) to large lesions on the vulva, vagina, cervix and some extragenital sites. Its prevalence in pregnancy varies from 5.5% to 65% depending on age, geography and gestational age (increas...
Source: Reproductive Biology - August 13, 2021 Category: Reproduction Medicine Authors: Victor N Chilaka Osric B Navti Mariam Al Beloushi Badredeen Ahmed Justin C Konje Source Type: research

Risk-benefit analysis of 9-valent HPV vaccination for adolescent boys from an individual perspective
Jpn J Infect Dis. 2021 Jul 30. doi: 10.7883/yoken.JJID.2021.367. Online ahead of print.ABSTRACTJapan recently approved quadrivalent human papillomavirus (HPV) vaccine for males, but 9-valent vaccine is only approved for females. Given the low female vaccination rate due to a concern of adverse events in Japan, quantifying the risk and benefit of the HPV vaccination for male may help the decision making to vaccinate adolescent boys in Japan. Using quality-adjusted life years, the risk-benefit ratio for an adolescent boy to get the 9-valent HPV vaccination was calculated. The male HPV vaccination reduced the QALY gain due to...
Source: Japanese Journal of Infectious Diseases - August 2, 2021 Category: Infectious Diseases Authors: Taito Kitano Source Type: research

Pages: 1  2  3